OTHER BLOGS

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression o..

Jun 05, 2023

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

Legend Biotech Announces Submission to the European Medicines Agency for Ex..

May 25, 2023

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

May 18, 2023

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Opt..

May 16, 2023

Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 million of American Depositary Shares

Legend Biotech Corporation Announces Pricing of Registered Direct Offering ..

May 08, 2023

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.